162011-76-9

Basic information

• Product Name: 2-(4-Fluorophenyl)-2-cyclopenten-1-one
• Synonyms: 2-(4-Fluorophenyl)-2-cyclopenten-1-one
• CAS NO: 162011-76-9
• Molecular Weight: 176.19
• Mol File: 162011-76-9.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 2-(4-Fluorophenyl)-2-cyclopenten-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-Fluorophenyl)-2-cyclopenten-1-one(162011-76-9)
• EPA Substance Registry System: 2-(4-Fluorophenyl)-2-cyclopenten-1-one(162011-76-9)

Safety Data

• Hazardous Substances Data: 162011-76-9(Hazardous Substances Data)

Upstream product

• 930-30-3 cyclopent-2-enone 
• 118798-76-8 tris(4-fluorophenyl)bismuth dichloride 
• 10481-34-2 2-bromo-2-cyclopenten-1-one 
• 1765-93-1 4-fluoroboronic acid 
• 3375-31-3 palladium diacetate 
• 628731-81-7 (+/-)-2-(4-fluorophenyl)cyclopent-2-enol 

Downstream Products

• 162011-77-0 1-(4-(methylthio)phenyl)-2-(4-fluorophenyl)-2-cyclopenten-1-ol 
• 628731-81-7 (+/-)-2-(4-fluorophenyl)cyclopent-2-enol 
• 1187791-73-6 5-bromo-2-(4-fluorophenyl)cyclopent-2-enone 

Relevant articles and documents

A Pd(II)-catalyzed ring-expansion reaction of cyclic 2-azidoalcohol derivatives: Synthesis of azaheterocycles

(Chemical Equation Presented) A Pd(II)-catalyzed ring expansion-reaction of cyclic 2-azidoalcohol derivatives was found to proceed via an unprecedented C-C bond cleavage-C-N bond formation sequence, providing substituted azaheterocycles.

Phosphine Catalyzed α-Arylation of Enones and Enals Using Hypervalent Bismuth Reagents: Regiospecific Enolate Arylation via Nucleophilic Catalysis

Exposure of enones and enals to 20 mol % tributylphosphine in the presence of triarylbismuth(V) dichlorides results in regiospecific aryl transfer to the α-position of the enone or enal pronucleophile. These results represent the first examples of enolate

Zwitterionic tachykinin receptor antagonists

The present invention is directed to certain novel compounds represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein R3, R5, R6, R7, R8, R11, R12 R13, Q, W, X, Y and Z are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of psychiatric disorders including depression and anxiety.